About Pluri
Pluri (TLV:PLUR), (NASDAQ:PLUR) is a cutting-edge firm dedicated to pioneering advancements in the realm of biotechnology. With a keen focus on developing innovative therapies and products, Pluri's operations span from research and development to commercialization, aiming to address some of the most pressing health challenges. The company's projects often revolve around regenerative medicine and cellular therapies, leveraging proprietary technologies to unlock new possibilities in treatment and recovery. Objectives at Pluri are centered around pushing the boundaries of science to improve patient outcomes, invest in sustainable solutions, and expand their presence in global markets. Through a blend of scientific expertise and strategic partnerships, Pluri is on a mission to transform the future of healthcare.
Snapshot
Operations
Products and/or services of Pluri
- AI music composition software enabling users to create original soundtracks based on a variety of genres and moods.
- Personalized AI language learning app offering tailored lessons and real-time feedback.
- Automated video editing tool that leverages machine learning to enhance footage and suggest edits.
- AI-driven analytics service for predicting market trends in the tech industry, helping businesses make informed decisions.
- Virtual reality platform for immersive educational experiences, focusing on history and science.
- Blockchain-based digital identity verification system ensuring secure and efficient online transactions.
Pluri executive team
- Mr. Yaacov YanayPresident, CEO & Director
- Ms. Liat ZaltsCFO & Treasurer
- Mr. Ori ShalemVice President of Operations & Manufacturing
- Mr. Lior RavivChief Technology Officer
- Dr. Arthur Machlenkin Ph.D.Chief Scientific Officer
- Ms. Hagit GalGeneral Counsel
- Ms. Nofar Glaich-DabachVice President of Human Resources
- Ms. Orly AmiranChief Quality Officer
- Ms. Efrat KaduriChief Business Development Officer of Pharma
- Mr. Nimrod Bar ZviChief Commercial Officer